NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 23 04:00PM ET
1.51
Dollar change
-0.11
Percentage change
-6.79
%
Index- P/E- EPS (ttm)-5.93 Insider Own42.76% Shs Outstand9.67M Perf Week-3.21%
Market Cap18.41M Forward P/E- EPS next Y-2.14 Insider Trans0.00% Shs Float6.98M Perf Month79.74%
Income-73.31M PEG- EPS next Q-1.23 Inst Own21.09% Short Float0.43% Perf Quarter-14.20%
Sales9.35M P/S1.97 EPS this Y4.32% Inst Trans8.35% Short Ratio0.26 Perf Half Y-45.88%
Book/sh2.82 P/B0.53 EPS next Y35.54% ROA-70.79% Short Interest0.03M Perf Year-98.24%
Cash/sh3.31 P/C0.46 EPS next 5Y23.89% ROE-105.79% 52W Range0.72 - 105.00 Perf YTD-24.88%
Dividend Est.- P/FCF- EPS past 5Y32.13% ROI-213.34% 52W High-98.56% Beta0.90
Dividend TTM- Quick Ratio3.61 Sales past 5Y39.00% Gross Margin73.24% 52W Low109.43% ATR (14)0.18
Dividend Ex-Date- Current Ratio3.61 EPS Y/Y TTM-12.53% Oper. Margin-801.02% RSI (14)57.23 Volatility12.53% 10.82%
Employees87 Debt/Eq0.02 Sales Y/Y TTM-82.54% Profit Margin-784.01% Recom3.00 Target Price2.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-207.71% Payout- Rel Volume1.94 Prev Close1.62
Sales Surprise-60.90% EPS Surprise-73.60% Sales Q/Q-94.52% EarningsFeb 28 BMO Avg Volume116.43K Price1.51
SMA2010.07% SMA5033.84% SMA200-42.43% Trades Volume225,776 Change-6.79%
Date Action Analyst Rating Change Price Target Change
Dec-20-24Downgrade RBC Capital Mkts Outperform → Sector Perform $48 → $2
Nov-15-24Reiterated RBC Capital Mkts Outperform $50 → $48
Dec-02-22Downgrade BofA Securities Buy → Underperform $0.50
Dec-02-22Downgrade BofA Securities Buy → Underperform
Nov-12-21Downgrade Morgan Stanley Overweight → Equal-Weight $6
Apr-08-21Initiated Morgan Stanley Overweight $19
Nov-03-20Initiated Truist Buy $21
Oct-26-20Initiated JMP Securities Mkt Outperform $19
Oct-19-20Resumed H.C. Wainwright Buy $16
Sep-27-19Initiated H.C. Wainwright Buy $15
May-23-25 10:42AM
Feb-20-25 03:06PM
Jan-31-25 07:21AM
Jan-30-25 07:00AM
Jan-10-25 02:00AM
11:23AM Loading…
Jan-08-25 11:23AM
Jan-07-25 04:05PM
02:00AM
Jan-06-25 02:00AM
Jan-02-25 02:00AM
Nov-22-24 06:51AM
06:35AM
Nov-14-24 04:05PM
Nov-11-24 04:05PM
Oct-31-24 09:17AM
07:30AM Loading…
Oct-30-24 07:30AM
Sep-24-24 07:30AM
Sep-02-24 09:55AM
Aug-30-24 08:00AM
Aug-28-24 08:57AM
Aug-08-24 04:30PM
Aug-07-24 09:55AM
Aug-01-24 10:01AM
Jul-22-24 08:30AM
Jul-08-24 07:01AM
Jul-02-24 06:32AM
Jul-01-24 04:31PM
Jun-04-24 01:00PM
May-30-24 04:30PM
May-23-24 05:01PM
02:27PM Loading…
May-16-24 02:27PM
May-09-24 11:55AM
07:01AM
Apr-25-24 07:01AM
Apr-24-24 12:31PM
07:01AM
Apr-16-24 04:30PM
Apr-10-24 07:01AM
Mar-22-24 01:52PM
08:15AM
07:01AM
Mar-06-24 07:01AM
Feb-02-24 12:00PM
Jan-29-24 08:01AM
Jan-16-24 07:01AM
Dec-21-23 09:15AM
07:01AM
Nov-20-23 07:01AM
Nov-09-23 08:39AM
07:01AM
Nov-03-23 12:01PM
Nov-02-23 04:01PM
Oct-22-23 06:01AM
Oct-18-23 07:01AM
Sep-13-23 08:45AM
Sep-12-23 07:01AM
Sep-06-23 08:17PM
07:01AM
Aug-15-23 10:20AM
Aug-10-23 08:40AM
07:01AM
Aug-03-23 07:01AM
Jul-12-23 07:22AM
Jun-10-23 05:00AM
May-31-23 09:30PM
04:45PM
May-16-23 06:08AM
May-11-23 08:25AM
07:01AM
May-09-23 05:35PM
07:01AM
May-04-23 07:02AM
07:01AM
Apr-26-23 11:30AM
Apr-19-23 07:00AM
Apr-14-23 04:01PM
Mar-18-23 03:12AM
Mar-17-23 06:35AM
Mar-16-23 04:18AM
Mar-15-23 08:15AM
07:00AM
Mar-13-23 07:00AM
Mar-08-23 07:00AM
Feb-13-23 07:00AM
Feb-07-23 07:00AM
Jan-04-23 07:00AM
Dec-20-22 09:11AM
Dec-15-22 07:00AM
Nov-30-22 07:00AM
Nov-16-22 05:39AM
Nov-14-22 08:15AM
07:00AM
Nov-08-22 03:40PM
Nov-07-22 10:00AM
07:00AM
Nov-02-22 10:01AM
07:00AM
Oct-20-22 07:00AM
Sep-29-22 12:00PM
Sep-27-22 08:07AM
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. It also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.